Clinical Trial Update: BI 113608 Administered as Tablets Twice Daily Over 4 Weeks in Patients With Chronic Obstructive Pulmonary Disease Associated With Chronic Bronchitis [Phase 1]

View source ↗

Summary

A Phase 1 trial evaluated the safety, tolerability, and pharmacokinetics of BI 113608 given as twice-daily tablets for 4 weeks in patients with chronic obstruct…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bronchitis
• Chronic Obstructive Pulmonary Disease

Drugs mentioned

• BI 113608

Snippet

Sponsor: Boehringer Ingelheim | Conditions: Pulmonary Disease, Chronic Obstructive | Phase 1 | Status: COMPLETED | Results posted: 2017-01-20